Arcturus Therapeutics Holdings EPS Ratio 2011-2026 | ARCT

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Arcturus Therapeutics Holdings

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.4	-3	-1.12	0.35	-7.74	-3.55	-2.15	-2.16	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
0.35	-7.74	-2.72

Quarterly EPS Ratio Arcturus Therapeutics Holdings

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.49	-0.34	-	-0.26	-0.64	-1	-	-0.61	-1.98	1.91	-	-1.33	-0.82	-1.94	-1.47	-2.05	-2.07	-2.15	-1.25	-0.92	-0.55	-0.67	-0.76	-0.56	-0.07	-0.68	-	-0.42	-0.99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.91	-2.15	-0.884

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	-0.49	$ 3.55	-0.28 %	$ 1.06 B	Canada
Adagene ADAG	-0.59	$ 3.91	-2.01 %	$ 220 M	China
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
AC Immune SA ACIU	-0.97	$ 3.32	6.07 %	$ 229 M	Schweiz
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-13.7	-	-10.17 %	$ 12.2 K	USA
ADC Therapeutics SA ADCT	-3.77	$ 4.11	-2.61 %	$ 105 M	Schweiz
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Aptorum Group Limited APM	-0.78	$ 0.79	0.04 %	$ 4.31 M	China
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
argenx SE ARGX	-7.99	$ 706.03	0.39 %	$ 25 B	Niderland
Alterity Therapeutics Limited ATHE	-0.53	$ 3.34	-7.48 %	$ 8.04 B	Australia
Ascendis Pharma A/S ASND	-8.28	$ 228.06	-1.28 %	$ 5 B	Danmark
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Can-Fite BioPharma Ltd. CANF	-0.01	$ 3.43	-4.19 %	$ 7.46 B	Israel
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-3.51	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	-5.64	$ 14.51	1.04 %	$ 213 M	USA
Aptinyx APTX	-0.96	-	-39.0 %	$ 4.57 M	USA
Applied Molecular Transport AMTI	-3.25	-	-	$ 10.1 M	USA
Aptose Biosciences APTO	-36.4	-	-45.71 %	$ 1.2 M	Canada
BioNTech SE BNTX	42.2	$ 94.86	4.77 %	$ 27.2 B	Germany
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
Aravive ARAV	-2.1	-	-13.39 %	$ 1.45 M	USA
Burford Capital Limited BUR	75.3	$ 8.28	2.86 %	$ 1.34 B	Britain
Athira Pharma ATHA	-2.52	-	-	$ 269 M	USA
Athersys ATHX	-0.39	-	3.77 %	$ 22.4 M	USA
Actinium Pharmaceuticals ATNM	-1.27	$ 1.14	2.7 %	$ 34.3 M	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-0.86	$ 1.51	-	$ 385 M	Britain
AVEO Pharmaceuticals AVEO	-1.63	-	-	$ 521 M	USA
Atea Pharmaceuticals AVIR	-1.94	$ 6.13	1.32 %	$ 500 M	USA
AVROBIO AVRO	0.27	-	1083.1 %	$ 745 M	USA
Equillium EQ	-0.38	$ 2.15	-7.33 %	$ 74.7 M	USA